{"url_path":"/sec/curx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022892-index.html","accession_number":"0001493152-26-022892","cik":"0002025942","ticker":"CURX","issuer_name":"Curanex Pharmaceuticals Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022892-index.html","primary_entity_key":"0002025942","primary_entity_name":"Curanex Pharmaceuticals Inc"},"word_count":219,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n31.1*\n \n[Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act](ex31-1.htm)\n\n \n \n \n\n31.2*\n \n[Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act](ex31-2.htm)\n\n \n \n \n\n32.1*\n \n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm)\n\n \n \n \n\n32.2*\n \n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm)\n\n \n \n \n\n101.INS*\n \nInline XBRL Instance Document\n\n101.INS*\n \nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline XBRL Taxonomy Extension Calculation Linkbase\nDocument\n\n101.DEF*\n \nInline XBRL Taxonomy Extension Definition Linkbase\nDocument\n\n101.LAB*\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Extension Presentation Linkbase\nDocument\n\n104\n \nCover Page Interactive Data File (formatted in Inline\nXBRL and contained in Exhibit 101)\n\n \n\n*\nFiled herewith\n\n \n\n25\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned thereunto duly authorized.\n\n \n\nDate: May 14, 2026\n**CURANEX PHARMACEUTICALS INC**\n\n \n \n \n\n \nBy:\n*/s/ Jun Liu                           *\n\n \nName:\nJun Liu\n\n \nTitle:\nChief Executive Officer and President\n\n \n \n(Principal Executive Officer)\n\n \n \n \n\nDated: May 14, 2026\nBy:\n*/s/ Wanjun Zhang*\n\n \nName:\nWanjun\nZhang\n\n \nTitle:\nChief Financial Officer\n\n \n \n(Principal Financial and Accounting Officer)\n\n \n\n26"}